Navigation Links
Carcinoid in Medical News

The AGA Foundation awards grant to Dr. Michael Choi to further his research on carcinoid tumors

Bethesda, MD (June 25, 2009) The AGA Foundation for Digestive Health and Nutrition (FDHN) has named Michael Y. Choi , MD, the first recipient of the Mary Terese Hartzheim Award for Neuroendocrine Tumor Research. This new research award was created for young investigators interested in researching...

Lexicon Initiates Phase 2 Clinical Trial of LX2931 in Patients With Rheumatoid Arthritis

...Phase 2 clinical trials, LX1031 for irritable bowel syndrome and LX1032 for carcinoid syndrome. Furthermore, LX4211 for diabetes has recently completed dosing i...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results

...tion of a Phase 2 study of LX1032 in patients with carcinoid syndrome," said Dr. Arthur T. Sands , president...on (FDA), into a Phase 2a study in patients with carcinoid syndrome . The Phase 2 clinical trial is designe...LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patient...

Carcinoid Cancer Foundation Sets Sights on Raising Awareness

...t the only cancers that catch victims by surprise. carcinoid cancer can go undetected for many years. Over 90% ...ectly diagnosed and treated for the wrong disease. carcinoid cancers are frequently diagnosed accidentally. carcinoid and related neuroendocrine tumors (NETs) grow slow...

Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results

...future upon achievement of certain milestones related to NEBIDO(R) (in development for hypogonadism) and octreotide (in development for acromegaly and carcinoid syndrome), two of the Company's primary product candidates. The acquisition will be effected by means of a tender offer for all the outstanding shares...

Frost & Sullivan Recognizes Neotropix's Approach to the Treatment of Small Cell Lung Cancer and Neuroendocrine Cancers

...o address unmet needs in the treatment of adults with small cell cancer and carcinoid cancer. It can also potentially treat children with neuroblastoma, Wilms' t...ts from Phase I/II open label clinical trials, which included both SCLC and carcinoid cancer patients, found that the majority of patients responded to NTX-010 t...

Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals

...reotide implant (in development for acromegaly and carcinoid syndrome), two of Indevus' primary product candida...keting and sale for the treatment of acromegaly or carcinoid syndrome. The tender offer is expected to com...thogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Abo...

Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. About Endo Pharmaceuticals Endo Pharmaceuticals is a specialty pharmaceutical company engaged in t...

Saturated Fats Linked to Cancer of Small Intestine

...ective study to examine the association between meat and fat intake and cancer of the small intestine. During the study, 60 adenocarcinomas and 80 carcinoid tumors of the small intestine were diagnosed among the participants, and an elevated risk for these cancers was associated with saturated fat intake, ...

Also in the Sept. 9 JNCI

...144 Experts Call for Renewed Efforts in Gastroenteropancreatic Neuroendocrine Tumors During a September 2007 summit on neuroendocrine and carcinoid tumor, clinicians and researchers presented the current standards of care and identified key areas that require investigation and development. Ove...
Carcinoid in Medical Technology

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

THE WOODLANDS, Texas, July 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan d...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown , senior vice president of clinical develop...

Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to inter...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...ning tumors (i.e., tumors that are associated with carcinoid syndrome due to the secretion of various hormones ...iarrhea/flushing episodes associated with advanced carcinoid tumors and profuse watery diarrhea associated with... used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive inte...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results

...ood and Drug Administration (FDA), into a Phase 2a study in patients with carcinoid syndrome . Lexicon has identified the clinical trial sites for this study...n currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which wer...

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Safe Harbor Statement This press release contains forward-looking statements within the mean...

Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. PRO 2000 PRO 2000 (a naphthalene sulfonate polymer) is under development as a topical vaginal micr...

New Study First to Confirm Sandostatin LAR(R) Depot Controls Tumor Growth in Patients With Rare Gastrointestinal Tumors

...etween the endocrine (hormonal) system and the nervous system, and includes carcinoid tumors and pancreatic NETs. Treatment options for patients with NETs are li...utes, octreotide has been used to treat symptoms associated with metastatic carcinoid tumors (flushing and diarrhea) and vasoactive intestinal peptide (VIP) secr...

RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors

...AR Depot therapy on survival in pancreatic NET and carcinoid patients EAST HAN... mixture of tumors that include pancreatic NET and carcinoid tumors. The development of NET is not completely u...to treat the diarrhea and flushing associated with carcinoid syndrome. The active ingredient in Sandostatin L...

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

... the debilitating symptoms of this disease. About carcinoid Cancer carcinoid tumors, or carcinoids, originate in hormone-produc...h the number increasing over the past 20-30 years. carcinoid tumors that metastasize to the liver have a poor p...
Carcinoid in Medical Definition

Pathology

...ome - 5-alpha-reductase deficiency - Hypogonadism - Delayed puberty - Precocious puberty Other Autoimmune polyendocrine syndrome - carcinoid syndrome - Laron syndrome - Psychogenic dwarfism - Androgen insensitivity syndrome - Progeria v • d • e Nut...
Carcinoid in Medical Dictionary

Lung tumor

...r ... What Are the Key Statistics About Lung carcinoid Tumor ? ... to suspect you may have a lung carcinoid tumor , your doctor will use one or more ... ...s into adjacent tissues and ... Symptoms of a carcinoid lung tumor include coughing up blood, wheezing...

Gastrointestinal

...r, Fox Chase Cancer Center offers comprehensive care Gastrointestinal carcinoid tumors develop from a certain type of hormone -making ... A gastrointestinal carcinoid tumor may also produce hormones. ... Gastrointestinal bleeding inf...

Carcinoid tumor

... carcinoid is a slow-growing type of neuroendocrine tumour, ... in the cells of the neuroendocrine system. carcinoid tumors produce the vasoactive substance, serotonin. ... carcinoid tumors arising in the bronchi may be associa...

Carcinoid syndrome

... Other components of the carcinoid syndrome are diarrhea (probably caused by ... Patients with carcinoid syndrome usually excrete >25 mg of 5-HIAA per day. ... Learn about carcinoid syndrome , get support, and find treatment opt...
Carcinoid in Biological News

Society of Interventional Radiology Foundation awards $191,000 in grants

...nu Gaur, Harvard Medical School, Boston, Mass., "Hepatic Arterial Chemoembolization (HACE), Yttrium-90 Radioembolization and Drug-eluting Bead-HACE in carcinoid Metastases to the Liver." ...
Carcinoid in Biological Technology

Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032 , the...

EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study

Combination of Panzem(R) NCD and Avastin(R) May Slow Tumor Growth ROCKVILLE, Md., Jan. 28 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the pre...

Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome

THE WOODLANDS, Texas, Dec. 21 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ) announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX1032, an oral drug candidate for managing gastrointest...

Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Delcath Systems Granted Third Orphan Drug Designation

... the drug melphalan for the treatment of neuroendocrine tumors metastatic to the liver. The trial is treating patients with pancreatic islet-cell and carcinoid tumors at the National Cancer Institute in Bethesda, Maryland. Commenting on this orphan-drug designation, Richard L. Taney, President and CEO of Del...

Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week

...naging gastrointestinal symptoms associated with carcinoid syndrome . The presentations will take place at ...X1032 is entering a Phase 2 study in patients with carcinoid syndrome. For more information on these pro... candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel s...

Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary ...

Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online

...scovering and developing breakthrough treatments for human disease. Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by the company's research team. The company has used its prop...

Indevus Pharmaceuticals Announces Release of 2008 Annual Report

... for hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, the octreotide implant for acromegaly and carcinoid syndrome, and pagoclone for stuttering. Contact: Michael W. Rogers EVP and Chief Financial Officer (781) 861-8444 Robin L....
Carcinoid in Biological Dictionary

Intestine

...appendix G ... structure of the intestine varies greatly in ... Small Intestine Cancer Key Terms: Adenocarcinoma , Angiosarcoma , Carcinogen , carcinoid , Leiomyosarcoma , Liposarcoma , Lymphoma , Malignant , In anatomy, the intestine is that tubular portion of the Gastrointestinal tract ... In hu...
Other Tags
(Date:11/26/2014)... 26, 2014 Bunion Bootie, the newest ... in an early celebration of the early holiday shopping ... offered at the promotional price of $29.95 each (normally ... addition to any automatic discounts applied when buying more ... website for complete details. It’s simple: purchasing more ...
(Date:11/26/2014)... 26, 2014 News Facts , ... capabilities at RSNA 2014 in Chicago. The company ... share diagnostic images, photos, videos and documents found ... #8107 will learn more about these innovative medical ... and partner initiatives – that enable more informed ...
(Date:11/26/2014)... (HealthDay News) -- Youngsters who enter puberty early are ... Early puberty was linked with a number of ... high anxiety levels, according to the researchers. Early puberty ... with family and peers, and having friends who were ... Although the study found an association between early puberty ...
(Date:11/26/2014)... of emergency department visits in the United States rose from ... in 2011, according to the U.S. Centers for Disease Control ... were going to ERs with non-urgent medical needs: 96 percent ... hours of arriving at the ER. In 2010, that number ... of patients arrived at the ER after normal business hours ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, 2014 (HealthDay ... disrupt the makeup of bacteria in the digestive system, potentially ... new study suggests. The research doesn,t confirm that ... and study authors aren,t recommending that anyone stop taking the ... used at the lowest dose that provides adequate relief of ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 2Health News:Perceptive Software to Demonstrate New Medical Content Management Features and Capabilities at RSNA 2014 3Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:ER Visits on the Rise, Study Reports 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
Other Contents